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Abstract
As a consequence of innate immune activation granulocytes and macrophages produce hypochlorite/hypochlorous acid
(HOCl) via secretion of myeloperoxidase (MPO) to the outside of the cells, where HOCl immediately reacts with proteins.
Most proteins that become altered by this system do not belong to the invading microorganism but to the host. While there
is no doubt that the myeloperoxidase system is capable of directly inactivating HIV-1, we hypothesized that it may have an
additional indirect mode of action. We show in this article that HOCl is able to chemically alter proteins and thus turn them
into Idea-Ps (Idea-P = immune defence-altered protein), potent amyloid-like and SH-groups capturing antiviral weapons
against HIV-1. HOCl-altered plasma proteins (Idea-PP) have the capacity to bind efficiently and with high affinity to the HIV-1
envelope protein gp120, and to its receptor CD4 as well as to the protein disulfide isomerase (PDI). Idea-PP was able to
inhibit viral infection and replication in a cell culture system as shown by reduced number of infected cells and of syncytia,
resulting in reduction of viral capsid protein p24 in the culture supernatant. The unmodified plasma protein fraction had no
effect. HOCl-altered isolated proteins antithrombin III and human serum albumin, taken as representative examples of the
whole pool of plasma proteins, were both able to exert the same activity of binding to gp120 and inhibition of viral
proliferation. These data offer an opportunity to improve the understanding of the intricacies of host-pathogen interactions
and allow the generation of the following hypothetical scheme: natural immune defense mechanisms generate by
posttranslational modification of plasma proteins a potent virucidal weapon that immobilizes the virus as well as inhibits
viral fusion and thus entry into the host cells. Furthermore simulation of this mechanism in vitro might provide an
interesting new therapeutic approach against microorganisms.
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Introduction
Despite recent advances in the understanding of HIV-1
infection, major scientific mysteries remain and HIV-1 infection
is still a global challenge for mankind. Viruses exclusively depend
on the host cellular machinery for their propagation and survival
and therefore need to invade into a host cell.
Genome entry into the target cell involves for the enveloped
HIV-1 several major steps. In most infections HIV-1 binds to a
cell-surface receptor and co-receptors; subsequently, as binding is
not sufficient for entry, the HIV-1 and the host cell membrane
fuse.
Membrane fusogenicity is the result of an active virus-host cell
interaction process that induces conformational changes within the
viral envelope protein [1].
Structural rearrangements within gp120 allow the binding to
co-receptors of the chemokine-receptor family, which aids in virus
entry. HIV-1 uses two important co-receptors. The chemokine
receptor CCR5 is the co-receptor utilized by macrophage- or M-
tropic viruses. They are referred to as R5 viruses [2]. The
chemokine receptor CXCR4 is the co-receptor for T-tropic or X4
viruses [3]. It is especially used by viruses appearing later in HIV-1
infection [4]. Dual-tropic HIV-1 strains use both co-receptors
(R5X4 strains).
The triggering of fusion requires cleavage of two of the nine
disulfide bonds of gp120 by the cell-surface protein disulfide-
isomerase (PDI) [5]. Activation of fusogenicity can result from
precise thiol/disulfide rearrangements mediated by either an
endogenous redox autocatalytic isomerase or a cell-associated
oxidoreductase [1]. In addition thiol/disulfide exchange in the
HIV-1 envelope protein is a prerequisite for CXCR4-tropic HIV-
1 envelope-mediated T-cell fusion [6].
To inhibit the contact between the envelope protein and its
receptor and co-receptors might therefore be an important target
for body defence.
The innate immune system is the first line of defence against
invading pathogens. Entry of HIV-1 into the host initiates
immediate responses to control virus propagation. Neutrophils
are recruited to sites of viral infection and act as the first line of
defence [7].
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Myeloperoxidase (MPO), a heme enzyme released from
azurophilic intracellular granules by activated neutrophils, is the
most abundant protein in neutrophils [8].
At physiological concentrations chloride is the most likely
substrate and hypochlorous acid (HOCl) has been shown to be a
major end-product [9]. The pKa values for of HOCl is 7.59, thus
at physiological pHs, approximately equal concentration of HOCl
and 2OCl will be present [10]. We use the term HOCl to describe
this mixture.
Klebanoff and colleagues showed already in the beginning of
the 90th that the myeloperoxidase/HOCl system of polymorpho-
nuclear leukocytes and mononuclear phagocytes has a virucidal
effect against HIV-1 [11,12]. In vitro the heme enzyme myeloper-
oxidase is very efficient in stopping HIV-1 propagation [13].
HOCl reacts with and kills microbes directly.
Myeloperoxidase can be released to the outside of the cell,
where it attacks normal tissue [14]. Segal found that the majority
of proteins that get oxidised by the myeloperoxidase hypohalide
system surprisingly belong to the host not the invaders [15].
Plasma proteins consume the majority of HOCl. HOCl-mediated
oxidation of the major plasma protein, albumin, was investigated
by Pattison et al [16].
While there is no doubt that the myeloperoxidase system is
capable of inactivating HIV-1 directly, it may have in addition an
indirect mode of action.
As proteins and amino acids are highly abundant in vivo and
react rapidly with HOCl, they are likely to be major targets for
HOCl [17]. Exposure of proteins to HOCl can result in the loss of
protein structure because of unfolding [18].
The finding that HOCl-altered proteins (we named them
immune defence-altered-proteins, Idea-Ps) were amyloid-like and
bound with high affinity to proteins offering free SH-groups and
the recently published knowledge on the amyloid-like ‘‘Semen-
derived Enhancer of Viral Infection’’ (SEVI) and the role of thiols
in HIV-1 entry prompted us to study whether Idea-Ps are able to
inhibit HIV-1 infection.
Results
1. Immune defence-altered pooled plasma proteins
(Idea-PP) bind with high affinity to HIV-1 gp120, its
receptor CD4 and to PDI
To investigate the consequences of protein modification by the
myeloperoxidase/HOCl immune defence system pooled plasma
proteins were isolated from human plasma, modified by HOCl to
generate Idea-PP and subsequently tested for their capacity to
bind to HIV-1 gp120, its receptor CD4 and to the PDI. As a
control unaltered pooled plasma proteins (PP) were used for the
binding studies. ELISA assays showed specific binding to gp120,
CD4 as well as to the PDI for Idea-PP, whereas binding of the
non-modified original material to GP120 and CD4 was not
significant (Fig. 1A, B). Some binding of the non-modified original
material to the PDI was observed, but the binding to the HOCl-
altered material was significantly higher.
Binding was confirmed by surface plasmon resonance (SPR)
spectrometry. SPR demonstrated that immobilized gp120, CD4 as
well as PDI bind Idea-PP with very high affinity (Fig. 1D, E, F).
The sensorgrams could have been fitted to a Langmuir model
using BiaEvaluation Software 3.1 (GE Healthcare) to gain
quantitative data, but the off-rates were too slow to be reliably
estimated by this method. The association phase of a BIAcore
experiment is also affected by the dissociation rate. Inherent in the
fitting method is in addition the assumption that the association
and dissociation rates are true for a one-to-one interaction model.
As Idea-PP is a mixture of proteins and several of them
oligomerize and presumably present several binding sites, this
model cannot be used and therefore no reliable quantitative data
can be given.
In all control experiments using unmodified plasma protein the
response units (RU) in SPR were below 10.
Thus Idea-PPs represent putative therapeutic agents to interfere
with viral binding to and fusion with host cells.
2. Idea-PP inhibit cellular infection by HIV-1 IIIB
In order to study the effect of Idea-PP on viral binding to and
fusion with human cells pooled plasma proteins (PP) were altered
to Idea-PP using different molar ratios of protein to HOCl; ratios
of 1:300, 1:1000 and 1:2000 were used for the experiments to
evaluate the optimal procedure. Neither Idea-PP nor the control
PP was toxic for the human cells in the used concentrations of up
to 50 mg/ml since the mitochondrial activity was not decreased.
(Fig. 2A, B)
The first assay to test the effect of Idea-PP on binding to and
fusion with human cells was based on an adherent CD4+ HeLa
cell line stably transfected with episomal vectors carrying the b-
galactosidase gene under the control of the HIV-1 long terminal
repeat (LTR) promoter. HIV-1 infection of these cells transacti-
vates the LTR promoter inducing b-galactosidase production.
Infected cells stained dark blue after the addition of the
chromogenic substrate X-Gal. All tested Idea-PP pools reduced
the number of HIV-1-infected cells in a dose dependent manner
(Fig. 2D, E, F), whereas the non-modified original material had no
effect (Fig. 2C). However the antiviral effect was more prominent
when Idea-PP was produced with a molar ratio of protein to
HOCl of 1:1000 (Fig. 2E: IC90 0.5 mg/ml, IC50 3.5 mg/ml)
compared to the material generated with a ratio 1:300 (Fig. 2D:
IC90 7 mg/ml, IC50 31 mg/ml). A higher ratio of 1:2000 did not
further increase the virus-inhibitory effect of Idea-PP (Fig. 2F:
IC90 0.5 mg/ml, IC50 3.5 mg/ml).
Light microscopy visualized that nearly all host cells treated with
the control pooled plasma protein (PP) were stained intensely blue,
showing to be infected by HIV-1 IIIB (Fig. 2G upper row), while
only sporadic host cells were infected by HIV-1 IIIB, when the
virus was pre-incubated with Idea-PP (1:1000) (Fig. 2H upper
row).
HIV-1 IIIB is capable of inducing syncytia formation of infected
host cells. Infected host cells fuse together induced by CD4-gp120
interaction on the plasma membrane to form large to giant cells
with several nuclei. Inhibition of syncytia formation by Idea-PP
was seen using M8166 cells, while pooled plasma protein control
had no effect (Fig. 2G lower row for PP control versus Fig. 2H
lower row for Idea-PP).
Pooled plasma protein control had in addition no influence on
the formation of HIV-1-induced HeLaT4-lacZ syncytia (Fig. 3A).
HIV-1 particles pre-incubated with increasing concentrations of
PP induced not less syncytia as those treated with medium only. In
contrast, the number of syncytia decreased, when the viral
particles were incubated with Idea-PP generated with different
molar ratios of protein:HOCl (Fig. 3C, E, G). As seen in the
previous experiment where the number of infected host cells was
quantified, Idea-PP prepared with a ratio of 1:1000 (protein:-
HOCl) was more effective to interfere with syncytia formation
than Idea-PP prepared with a ratio of 1:300 (Fig. 3C: IC90 2 mg/
ml, IC90 16 mg/ml, Fig. 3E: IC90 0.5 mg/ml, IC50 3.5 mg/ml). A
higher ratio of 1:2000 could not further increase the inhibitory
effect of Idea-PP on virus induced syncytia formation (Fig. 3G:
IC90 0.5 mg/ml, IC50 3.5 mg/ml).
Weapons against HIV-1
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Measuring the HIV-1 major capsid protein p24 antigen in cell
culture supernatant is a long-established method for virus
quantification. While unmodified pooled plasma proteins did not
reduce the amount of p24 in the cell supernatant (Fig. 3B) Idea-PP
decreased the p24 levels in a dose-dependent manner (Fig. 3D:
IC90 11 mg/ml, IC50 30 mg/ml; Fig. 3F: IC90 2 mg/ml, IC50
Figure 1. Binding of pooled plasma proteins (PP) and HOCl-altered pooled plasma proteins (Idea-PP) to gp120, CD4 and PDI.
Binding of either plasma proteins (PP) or altered plasma proteins (Idea-PP) to purified HIV-1 gp120 (A), CD4 (B) or PDI (C), respectively was determined
by specific ELISA. The mean extinction6 SD from three parallel samples is presented. Surface plasmon resonance sensorgrams of the binding of Idea-
PP to gp 120 (Fig. 1 D), to CD4 (Fig. 1 E), and to PDI (Fig. 1 F) showed high affinity.
doi:10.1371/journal.pone.0066073.g001
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5 mg/ml; Fig. 3H: IC90 2.5 mg/ml, IC50 4.5 mg/ml). These
results correspond to those seen for the number of syncytia.
3. Idea-PP also inhibits other X4-tropic as well as R5X4-
tropic HIV-1 strains
To answer the question whether inhibition of HIV-1 is strain-
specific or represents a more general phenomenon, we tested the
capacity of Idea-PP to inhibit other HIV-1 isolates than IIIB.
Infection of HeLaT4-lacZ by another X4-tropic viral strain, NL4-
3, was significantly reduced by pre-incubation of the HIV-1
particle with Idea-PP prepared with a molar ratio of protein:-
HOCl of 1:1000 (Fig. 4A).
Infection of HeLaT4-lacZ by the R5X4-tropic HIV-1 clone
93BR020 (subtype F), a primary isolate by WHO from a Brazilian
patient in 1993, was inhibited by pre-incubation with Idea-PP
prepared at molar ratios of protein:HOCl of 1:1000 (IC90 2 mg/
ml, IC50 13 mg/ml or 1:2000 (IC90 0.1 mg/ml, IC50 0.8 mg/ml)
(Fig. 4B, C) in a dose-dependent manner. The effect of Idea-PP
prepared with a molar ratio of protein:HOCl of 1:300 was less
prominent (Fig. 4D) and control PP had no effect (Fig. 4E).
4. Isolated single immune defence-altered proteins (Idea-
Ps) show antiviral activity
In a further set of experiments we evaluated purified plasma
proteins before and after alteration with HOCl for their capacity
to interfere with viral infectivity. For that reason we chose human
serum albumin (HSA) as the most prominent plasma protein and
antithrombin III (ATIII), as representatives for all plasma proteins,
and compared the antiviral effect of their modified forms with that
of the corresponding unmodified proteins.
Inhibition of viral infection by Idea-HSA in comparison to HSA
could be observed as reduction of infected cells (Fig. 5A, B; Fig. 5E
upper row versus Fig. 5F upper row) (Fig. 5B: IC90 0.7 mg/ml,
IC50 3.5 mg/ml) as well as a decrease in the number of syncytia
(Fig. 5C, D; Fig. 5E lower row versus Fig. 5F lower row) (Fig. 5D:
IC90 1.5 mg/ml, IC50 4.5 mg/ml).
The antiviral effect of Idea-HSA was not limited to X4-tropic
isolate IIIB, since the dualtropic primary isolate 93BR030 was also
inactivated by contact with Idea-HSA (Fig. 5G, H).
To verify, that acquiring antiviral activity by modification with
HOCl is not restricted to albumin, we included modified
antithrombin III in our experiments. When HIV-1 was pre-
incubated with increasing concentrations of Idea-ATIII the
infectivity of the virus was highly decreased as shown by reduced
number of infected HeLaT4-lacZ cells and lower amounts of
syncytia (Fig. 6A: IC90 0.2 mg/ml, IC50 1 mg/ml; Fig. 6C: IC90
0.1 mg/ml, IC50 0.8 mg/ml). No effect was visible when the virus
was incubated with unmodified ATIII (Fig. 6B, D). Surface
Plasmon Resonance (SPR) was used to monitor the interactions in
real time.
As seen with altered plasma protein mixture Idea-ATIII showed
also high-affinity binding to gp120 (Fig. 6E), to CD4 (Fig. 6F) and
to the PDI (Fig. 6G). Reliable on and off rates and dissociation rate
constants kd [s
21
] can not be given, as the KD is dependent on
both the association (on) and dissociation (off) rates of the
compound and the off-rates were too slow to be meaningfully
determined.
In addition to antithrombin III and HSA we tested fibrinogen,
coagulation factor VIII and bovine serum albumin. All these
proteins were successfully transformed into antiviral agents by
alteration with HOCl.
5. Mechanism of antiviral activity by Idea-P
As the Idea-proteins used in this study tended to oligomerize
and aggregate in contrast to the unmodified proteins, we tested
whether they are partially unfolded or misfolded by the HOCl
treatment and therefore amyloid-like. Coagulation factor XII
(FXII), tissue plasminogen activator (tPA) and the chaperone BiP,
all proteins capable to bind proteins with amyloid-like properties,
bound all tested Idea-proteins (Idea-PP, Idea-HSA, Idea-ATIII)
(figure S1) and HOCl treatment of proteins induced oligomerisa-
tion. In addition we previously made the observation that Idea-P
bound reduced glutathione, GSH. To further clarify the mecha-
nism how Idea-Ps exert their antiviral activity we tested therefore
the hypothesis that the binding of Idea-P to gp120, CD4 and PDI,
respectively, is at least partially thiol-mediated.
The inhibitor of free sulfhydryls that does not penetrate the
membrane, 5,59-Dithio-bis(2-nitrobenzoic-acid) (DTNB), was used
to examine the role of ecto-sulfhydryls in the interaction of Idea-P
with gp120, CD4 and PDI.
The viral envelope protein gp120, its receptor CD4 or PDI,
respectively, were pre-incubated with increasing concentrations of
the thiol blocker DTNB. Binding of Idea-HSA to gp120, to CD4
as well as to PDI were inhibited by DTNB (Fig. 7A, B, C). In
addition the binding of Idea-PP, Idea-ATIII and other HOCl-
altered proteins was inhibited by the direct thiol blocker (data not
shown).
HOCl-treatment of proteins can lead to the formation of a, b-
unsaturated aldehydes. These can react with lysine groups to form
the SH-binding form Ne-(3-formyl-3,4-dehydropiperidino) lysine
(FDP-lysine) group. Therefore we tested whether Idea-Ps with
antiviral activity contain FDP-lysine groups.
A specific monoclonal antibody against FDP-lysine bound
specifically and dose-dependently to all our Idea-P preparations.
Fig. 7 D shows the binding of the anti FDP-lysine monoclonal
antibody to Idea-HSA, but not to HSA.
Discussion
Neutrophils mediate important human innate immune respons-
es to infection. Host defence against microbial invaders is initiated
by the respiratory burst, in which nicotinamide adenine dinucle-
otide phosphate (NADPH) oxidase generates vast amounts of
superoxide anions. The enzyme myeloperoxidase (MPO) uses
hydrogen peroxide and chloride as a co-substrate to generate
hypochlorous acid, a potent antimicrobial agent. While killing of
microorganisms was previously believed to be accomplished
directly by free oxygen radicals and by oxidized halides, the
group of Segal showed that the killing activity of neutrophils is
mediated mainly through activation of proteases by K+ flux
Figure 2. Effect of plasma proteins (PP) and HOCl-altered plasma proteins (Idea-PP) on HIV-1 infection. A putative toxicity of PP (A) or
Idea-PP modified in a protein:HOCl ratio of 1:2000 (B) was controlled by measuring mitochondrial activity of HeLa-T4lacZ cells with MTS assay. Idea-PP
is not toxic to host cells in the used concentrations. The optical density is presented as mean 6 SD from three parallel samples. The X4-tropic HIV-1-
isolate IIIB was pre-incubated for 1 h with purified plasma proteins, either unaltered (C) or modified by HOCl in a ratio PP:HOCl of 1:300 (D), 1:1000 (E),
or 1:2000 (F) and given to HeLa-T4lacZ cells. The number of infected cells was quantified after 4d from four parallel samples (C; D, E; F). Microscopic
view on HIV-1-infected HeLa-T4lacZ cells (G, H upper part) and M8166 monocytes (G, H lower part). HIV-1-IIIB was pre-incubated for 1 h either with PP
(E) or with Idea-PP, modified with HOCl in a ratio 1:2000 (F) and added to the cells; the cells were visualized after 4d (G, H).
doi:10.1371/journal.pone.0066073.g002
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[19,20]. Neutrophils cooperate with extracellular agents as well as
other immune cells to optimally kill and degrade invading
microbes [21]. Intense activation by microbial or inflammatory
stimuli triggers neutrophil degranulation. It involves granule
translocation to the plasma membrane followed by exocytosis, a
tightly regulated process [22]. Excessive degranulation of azur-
ophilic, primary granules from neutrophils is a central feature in
numerous inflammatory disorders, like cardiovascular disease [23].
As proteins and amino acids are highly abundant in vivo and
react rapidly with HOCl, they are likely to be major targets for
HOCl [16,17]. Oxidation by myeloperoxidase-derived HOCl can
cause both a loss of function of protease inhibitors and lysozyme
[24], but also a gain of function has been reported [25]. Most
proteins that become altered by the myeloperoxidase/HOCl
system do not belong to the invading microorganisms, but to the
host [20]. We speculated, that HOCl-altered host proteins might
Figure 3. Effect of plasma proteins (PP) and HOCl-altered plasma proteins (Idea-PP) on HIV-1-induced syncytia formation and viral
replication. The X4-tropic HIV-1-isolate IIIB was pre-incubated for 1 h with purified plasma proteins, either unaltered (A,B) or modified by HOCl in a
ratio PP:HOCl of 1:300 (C,D), 1:1000 (E,F), or 1:2000 (G,H) and given to HeLa-T4lacZ cells. After 4d the number of syncytia (A,C,E,G) was quantified
microscopically and the amount of p24 in the culture supernatant (B,D,F,H) was measured by ELISA. The values are given as mean 6 SD from four
parallel samples.
doi:10.1371/journal.pone.0066073.g003
Figure 4. Effect of plasma proteins (PP) and HOCl-altered plasma proteins (Idea-PP) on cellular infection by different HIV-1 isolates.
The X4-tropic HIV-1 isolate NL4-3 was pre-treated with the same substances and given to HeLaT4-lacZ cells (A). The number of infected cells was
quantified after 4d, the values are given as mean6 SD from four parallel samples. The R5X4-tropic HIV-1 isolate 93BR020 (B–E) was pre-incubated for
1 h with purified plasma proteins, either unaltered (E) or modified by HOCl in a ratio PP:HOCl of 1:300 (D), 1:1000 (B), or 1:2000 (C) and given to HeLa-
T4lacZ cells.
doi:10.1371/journal.pone.0066073.g004
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Figure 5. Effect of human serum albumin (HSA) and HOCl-altered HSA (Idea-HSA) on HIV-1 infection. The X4-tropic HIV-1-isolate IIIB
was pre-incubated for 1 h with purified HSA, either unaltered (A,C) or modified by HOCl in a ratio HSA:HOCl of 1:1000 (B,D) and given to HeLa-T4lacZ
cells. The number of infected cells (A,B) and the number of syncytia (C,D) was quantified after 4d from four parallel samples. (E,F) Microscopic view on
HIV-1-infected HeLa-T4lacZ cells (E, F upper part) and M8166 monocytes (E, F lower part). HIV-1-IIIB was pre-incubated either with HSA (E) or with
Weapons against HIV-1
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have a role in host defence. Therefore plasma proteins were
modified by the myeloperoxidase/HOCl system. The altered
protein mixture still bound to immobilized GSH after very
carefully removal of HOCl. As HIV-1-gp120 [26], host cell CD4
[27], and the PDI [28] all present ecto-sulfhydryls essential for
HIV-1 entry, it was examined whether Idea-PP is able to bind to
these proteins. Using ELISA and plasmon resonance technique
specific and high affinity binding of Idea-PP to gp120, CD4 as well
as to the PDI was observed.
However, the off-rates were very slow (,561025 s21), and
analysis of slow dissociation rates using Biacore is really
challenging [29]. As HOCl altered proteins oligomerize and
several binding sites may be presented on Idea-Ps to gp120, CD4
as well as the PDI avidity effects from multivalent binding may
obscure the intrinsic thermodynamic affinities of the single binding
sites. The sensorgrams indicate very tight binding but giving
binding parameters and calculate affinities by the surface plasmon
resonance (SPR) data would not be meaningful.
Binding of Idea-PP to gp120, CD4 and PDI prompted us to
speculate, that the body might make use of Idea-PP as viral entry
inhibitors. MTS cell viability assay to determine potential
cytotoxicity of Idea-PP documented that neither control PP nor
Idea-PP were toxic to host cells and therefore were used in
subsequent testing on HIV-1 infectivity.
The effect of Idea-PP was thereon examined using three
different, independent test systems. Idea-PP, but not control PP,
inhibited in a dose-dependent manner cellular infection by HIV-1
IIIB as documented by a semi-quantitative assay based on the
transactivation of the HIV-1 LTR promoter. IdeaPP manufac-
tured with a ratio of 1:300 (PP:HOCl) was less effective than Idea-
PP produced with a ratio of 1:1000. Using more HOCl for Idea-
PP preparation did not further intensify the effect of the Idea-PP.
The morphology of all Idea-PP or PP treated cells looked perfectly
normal.
HIV-1 infection in vitro can induce syncytia formation, giant
multinuclear cells that are generated by cell fusion [30]. Idea-PP
but not PP inhibited HIV-1 IIIB-induced syncytia formation and
interfered with infectivity in HeLaT4-lacZ cells in a dose-
dependent manner. Again Idea-PP prepared with a ratio of
1:1000 (PP:HOCl) was most effective. Furthermore viral propa-
gation in the cell culture could nearly completely be abolished by
pre-incubation of HIV-1 particles with Idea-PP, but not with PP
control as shown with p24 assay. The culture-adapted HIV-1 IIIB
strain is X4-tropic and infects mainly T-cells. Therefore further
experiments were performed with another X4-tropic viral strain,
NL4-3, and a primary isolate from a patient the R5X4 tropic
HIV-1 clone 93BR020 (subtype F9). Inhibition of infectivity,
syncytia formation and viral propagation showed that the anti
HIV-1-effect of Idea-PP is more general at least to X4-tropic HIV-
1 strains.
The next step was to elucidate, whether the myeloperoxidase/
HOCl system can transform also isolated single proteins into
antiviral weapons. As albumin is the most abundant plasma
protein human serum albumin was altered with HOCl to Idea-
HSA. As seen with Idea-PP mixture Idea-HSA reduced in a dose-
dependent manner the number of cells infected by the X4-tropic
isolate HIV-1 IIIB as well as the dual tropic isolate 93BR030. To
test whether the transformation into an antiviral weapon is human
albumin specific, several other plasma proteins were treated with
HOCl. Antithrombin III, coagulation factor VIII and bovine
serum albumin were altered to produce Idea-ATIII, Idea-FVIII,
Idea-BSA. As shown for Idea-HSA, each one of the other altered
plasma proteins reduced the number of HIV-1 infected cells and
lowered the amounts of HIV-1 induced syncytia. For Idea-ATIII
and Idea-HSA binding to gp120, CD4 and to the PDI with high
affinity, was demonstrated [31,32].
Naturally occurring fragments of the prostatic acidic phospha-
tase (PAP) form amyloid fibrils termed Semen-derived Enhancer
of Virus Infection (SEVI), capture HIV-1 particles and promote
their attachment to target cells, thereby enhancing the infectious
virus titre by several orders of magnitude [33]. These data show
clearly that the HIV-1 binds to amyloidogenic proteins.
Winter et al demonstrated that low molar ratios of HOCl to
protein cause oxidative protein unfolding [34]. All the HOCl
modified proteins used in this work showed amyloid-like proper-
ties, as they oligomerized, tended to aggregate and bound to the
general amyloid recognizing proteins tPA, FXII and the chaper-
one BiP. Other proteins, shown to interact with HIV-1 and to
inhibit HIV-1 infection, are also known to have amyloid-like
properties. One of these proteins is thrombospondin-1 [35].
Thrombospondin-1 aggegated the virus and inhibited viral
propagation by binding to the env-protein [36]. Later Thrombos-
pondin-1 was demonstrated to share structural properties with
amyloid proteins [37]. The alpha-defensins, Human Neutrophil
Peptide-1–3, exhibited anti-HIV-1 activity on at least two levels:
directly inactivating virus particles; and affecting the ability of
target CD4 cells to replicate the virus [38]. Human alpha defensins
1–3 bind to tPA [39], oligomerize in the presence of a membrane
and bind to the chaperone protein BiP [40]. In that way they seem
to act like amyloid-like proteins. Human neutrophil alpha
defensins 1–3 are in addition able to induce amyloid-like structures
in adhesion proteins like fibrinogen, von Willebrand factor,
fibronectin and thrombospondin-1 [40].
As amyloid-like proteins bind to HIV-1, oligomerize, and
built aggregates and nets, they will probably immobilize
the virus!
Neutrophils contribute to pathogen clearance by producing
neutrophil extracellular traps (NETs). Akong-Moore et al [41] very
recently studied NETs formation and found that, while exogenous
addition of H2O2 and HOCl stimulated NETosis, only exogenous
HOCl could rescue NETosis in the setting of MPO inhibition.
The myeloperoxidase associated with neutrophil extracellular
traps is active [42], and therefore likely producing Idea-Ps.
Recently Saitoh et al [43] showed that NETs in addition to
bacteria and fungi also capture the human immunodeficiency
virus. Idea-proteins are very special amyloid-like proteins, as they
have a second mode of action to interfere with HIV-1-infection.
Meshes built by chromatin strands and by amyloid-like Idea-Ps
may support each other.
Idea-proteins bind to immobilized GSH and binding of Idea-
proteins to gp120, CD4 and to the PDI was inhibited by DTNB,
showing, that Idea-P likely is interacting with the ecto-sulfhydryls
of gp120, CD4 and PDI. Treatment of plasma protein with the
myeloperoxidase/HOCl system was shown to lead to the
conversion of L-threonine into 2-hydroxypropanal and its
dehydration product, acrolein (2-propenal), an extremely reactive
a, b-unsaturated aldehyde [44]. Aldehyde production was also
mimicked by hypochlorous acid (HOCl) in the absence of the
Idea-HSA (F) and added to the cells; the cells were visualized after 4d. The dualtropic HIV-1-strain 93BR020 was pre-incubated with either HSA (G) or
with IDEA-HSA 1:1000 (H). Numbers of infected cells after 4d are presented as mean 6 SD from four parallel samples.
doi:10.1371/journal.pone.0066073.g005
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Figure 6. Effect of antithrombin III (ATIII) and HOCl-altered ATIII (Idea-ATIII) on HIV-1 infection. The X4-tropic HIV-1-isolate IIIB was pre-
incubated for 1 h with purified ATIII, either unaltered (A,C) or modified by HOCl in a ratio 1:1000 (B,D) and given to HeLa-T4lacZ cells. The number of
infected cells (A,B) and the number of syncytia (C,D) per well was quantified microscopically after 4d. Numbers are presented as mean6 SD from four
parallel samples. Surface plasmon resonance sensorgrams of the binding of Idea-ATIII to gp120 (E), to CD4 (F), and to PDI (G) showed high affinity.
doi:10.1371/journal.pone.0066073.g006
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enzyme. In a murine model of acute myocardial infarction, the
myeloperoxidase/HOCl system was found to be a major source of
acrolein [45]. The a,b-unsaturated aldehyde acrolein can form bis-
adducts with lysine residues, which are called FDP-lysines [46]. The
electrophilic a,b-unsaturated carbonyl moiety is retained in FDP-
lysine, allowing it to undergo a nucleophilic addition of thiols [47].
Protein-conjugated FDP-lysine was detected by the FDP-lysine
specific antibody F56 [46]. Using antibody F56 we documented that
Idea-HSA, but not the unmodified mother protein HSA, contained
FDP-lysine residues. As Idea-Ps binding to gp120, CD4 and PDI is
inhibited by DTNB and Idea-Ps clearly contain accessible chemical
groups that react eagerly with free SH groups, it is likely that SH-
groups are at least in part involved in the interaction between Idea-
Ps and HIV-1. FDP-lysine groups have been shown to bind
covalently to free SH groups of the protein glyceraldehyde-3-
phosphate dehydrogenase [47]. Probably FDP-lysine groups in
Idea-Ps will also link Idea-Ps to its targets on HIV-1 in a covalent
manner. The very slow off rates seen in the sensorgrams of the
plasmon resonance data support this interpretation.
In conclusion we postulate that the myeloperoxidase/HOCl
system, in addition to its other roles in host defence, works as a
mechanism to form HIV-1 entry inhibitors by forming amyloid-
like proteins that immobilizes the virus and by the generation of
FDP-lysine residues on these proteins that attack ecto-sulfhydryls
in gp120, CD4 and in the PDI (Fig. 8).
The question, why there are not enough Idea-Ps to combat
HIV-1 invasion, might be answered by the observation that there
is significant impairment of neutrophil function in advanced HIV-
1 infection and by the recent observation that the HIV-1
counteracts neutrophil response [41]. In addition to neutropenia,
a variety of qualitative defects in neutrophil function has been
described in HIV-1 infection [48–50].
Other microorganisms depend on an amyloid coat to attach to
host cells [51] and on active thiols for entry into the host cell as well.
The coxsackievirus A9 and dengue fever virus serotype 2 use the
amyloid recognizing chaperone BiP as a co-receptor for virus
internalization [52,53]. Ryser et al described that HIV-1 entry into
host cells can be inhibited by bacitracin [28]. Bacitracin is usually
considered to be a specific inhibitor of PDI activity. Recently,
however, bacitracin has been shown to have in addition significant
effects on both no catalyzed protein folding and on other molecular
chaperones. Especially bacitracin significantly inhibits the chaper-
one activity of BiP, the general binding protein for amyloid-like
proteins [54]. As Idea-proteins bind to BiP and the known HIV-1
Figure 7. Binding of HIV-1-gp120, CD4 and PDI to HOCl-altered HSA (Idea-HSA) in the presence of cell impermeable thiol blocker
DTNB and detection of FDP-lysine on Idea-HSA. The HIV-1 envelope protein gp120 (A), CD4 (B) and PDI (C) were pre-incubated with increasing
concentrations of the thiol reagent DTNB. Binding of Idea-HSA (1 mg/ml) was quantified by a specific ELISA. The extinction is given as mean 6 SD
from three parallel samples. Idea-HSA (D) and HSA were immobilized and the binding of the FDP-lysine specific monoclonal antibody (clone 5F6) was
tested by ELISA. The extinction is given as mean 6 SD from three parallel samples.
doi:10.1371/journal.pone.0066073.g007
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entry inhibitor bacitracin inhibits BiP, it is likely that in addition to
the chaperone PDI, the chaperone GRP78/BiP, a principal sensor
for amyloidogenic proteins, is involved in HIV-1-infection.
Involvement of cell surface BiP would also explain the enhancement
of HIV-1 infectivity by Semen-derived Enhancer of Virus Infection
(SEVI). As other viruses have been shown to use BiP for
internalisation [55,56] Idea-proteins might also be useful as
inhibitors of other virus infections. Jain et al observed that blocking
the production of free thiols by thiol-disulfide exchange inhibitors of
the fusion protein (F) of the Newcastle disease virus (NDV) the F
protein inhibited membrane fusion required for viral entry and cell-
cell fusion [57]. The role of thiol-disulfide exchange in host cell
entry/invasion is not restricted to viruses. According to Conant et al
Chlamydia attachment to mammalian cells requires protein disulfide
isomerase [58], and disulfide oxidoreductase activity of Shigella
flexneri is required for invasion of epithelial cells [59]. The protein
disulfide isomerase of the parasite Neospora canium is involved in
tachyzoite-host cell interaction [60].The PDI was even identified to
play an important role in cancer cell (glioma) invasion [61].
Therefore our newly discovered neutrophil function might be of
general relevance to path physiology.
Materials and Methods
Ethic Statement
Ethics approval for this study was obtained from the Innsbruck
Medical University, Austria.
The PBMCs were separated from a blood donation. Written
informed consent was obtained from the participating, anon-
ymized blood donors by the Central Institute for Blood
Transfusion and Immunological Department, Innsbruck, Austria.
Cell lines and culture
The human epithelial-like cell line HeLa-T4 PBK-LTRLac are
adherent CD4-positive cells, stably transfected with an episomal
vector carrying the Escherichia coli b-galactosidase gene under the
control of the HIV-1 long terminal repeat (LTR) promoter [62].
The cell line was purchased from the Programme EVA Centre for
AIDS Reagents (Hertfordshire, UK) and cultured in DMEM
medium (Life Technologies, Vienna, Austria) supplemented with
10% fetal calf serum (FCS; BioWhittaker, Verviers, Belgium),
penicillin/streptomycin (100 U/ml and 100 mg/ml, respectively),
2 mM L-glutamine (Life Technologies), 1 mg/ml geneticin
(selection for CD4 antigen; Sigma) and 100 mg/ml hygromycin
B (selection for pBK-LTRLac episome; Sigma).
The T-lymphoblastoid cell line M8166 was cultivated in RPMI
1640 medium (Life Technologies) supplemented with 10% FCS,
penicillin/streptomycin and 2 mM L-glutamine.
Virus propagation and purification
The X4-tropic HIV-1 strain IIIB (subtype B) was from the
MRC [63,64] and grown for propagation in the cell line M8166.
The R5X4-tropic HIV-1 clone 93BR020 (subtype F) was isolated
Figure 8. Hypothetical mechanism of blocking HIV-1-entry by Idea-P.We postulate that the myeloperoxidase/HOCl system, in addition to its
other roles in host defence, works as a mechanism to form HIV-1 inhibitors by forming amyloid-like proteins that immobilizes the virus and by the
generation of FDP-lysine residues on these proteins that attack ecto-sulfhydryls in gp120, CD4 and in the PDI. Idea-proteins have an amyloid-like
structure and bind with high affinity to proteins and regents offering free thiol groups. As these amyloid-like proteins bind to HIV-1, oligomerize, and
built aggregates and nets, they will probably immobilize the virus and interfere with its binding to the cell surface chaperone GRP78/BiP. High affinity
binding was shown to gp120, CD4 as well as to PDI. Thiol-blocker DTNB inhibited the binding of Idea-P to gp120, CD4 and PDI showing that the
binding was SH-dependent. Other proteins involved in HIV-1 entry that offer free SH-groups are thioredoxin, a 12-kD redox protein, necessary for
disulfide exchange in domain 2 of CD4, and the protein disulfide isomerase (PDI), essential for reduction of gp120 disulfide bonds, which triggers the
major conformational changes in gp120 and gp41 required for virus entry. We hypothesize that Idea-P can inhibit on several levels HIV-1 entry by
immobilization and by blocking free thiols.
doi:10.1371/journal.pone.0066073.g008
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by WHO from a brazilean patient in 1993 [65] and propagated in
human peripheral blood mononuclear cells (PBMC), isolated from
healthy human blood donors. The X4-tropic viral strain NL4-3
was purchased from AIDS Research and Reference Reagent
Program, NIAID, NIH [64]. This virus is a full-length, replication
and infection competent chimera with the 59 fragment derived
from proviral NY5 and the 39 fragment from proviral LAV.
Virus-containing cell culture supernatants were harvested 3
days after infection and filtered to remove cell debris. Viral
particles were purified by ultracentrifugation at 20,000 g for 1 h;
the pellet was resuspended in RPMI medium and frozen at
280uC.
Viral yield was determined by p24 antigen ELISA developed at
the Institute of Applied Microbiology (Vienna, Austria). For that
assay the monoclonal antibodies 37G12 and Mo1 were used, a
kind gift from H. Katinger (Institute for Applied Microbiology).
Briefly, microplates were coated overnight with the first mono-
clonal antibody and washed three times with PBS/0.1% Tween20
(Serva, Heidelberg, Germany). Dilution series of viral stocks were
applied on the plate, together with the second antibody conjugated
with biotin, for 1 h. The plates were consequently incubated with
streptavidin-b-galactosidase (Roche, Wien, Austria) for 30 min.
The amount of bound p24 was quantified by adding resorufin-b-
D-galactopyranoside substrate solution (Sigma, St. Louis, USA)
and measuring the optical density at 550 nm using an ELISA
reader. The p24 assay was calibrated using baculovirus-derived
recombinant p24 as a standard.
Preparation of Idea-P
Normal purified human proteins were transformed into the
antiviral form (Idea-Ps) by adding HOCl, to mimic the action of
the myeloperoxidase/H2O2/HOCl system, in a molar ratio
(protein:HOCl 1:100 to 1.2000) as given in the results. To alter
complex plasma protein compositions the estimated averaged
molecular weight of 70 kD for the proteins was taken as a basis. In
brief, freshly prepared HOCl was added to the protein in
phosphate buffered salt solution (PBS, pH 7.2) and the mixture
was incubated for 30 min at RT. Remaining HOCl was separated
by gel-filtration using sephadex G25 PD10 columns (GE
Healthcare). To transform protein mixture from human plasma
into immune defence-altered plasma protein (Idea-PP), proteins
were precipitated from human plasma with ammonium sulfate,
dialysed to remove the ammonium sulfate and then modified
directly with freshly prepared HOCl.
Idea-P toxicity tests
To examine a potential toxicity of Idea-Ps, the HeLa cells were
incubated with increasing amounts of the substances and the
mitochondrial activity was analyzed using a commercially
available test kit according to manufacturer’s instruction (Pro-
mega, Madison, USA). After 4 days MTS reagent was added to
the cells and its conversion by active mitochondrial enzymes was
measured in an ELISA-reader by determining the optical density
at dual wavelengths at 492 nm and 620 nm.
Virus infection and neutralization by Idea-Ps
The HeLa CD4+ cell line was infected with the different viruses
at a concentration of 40–400 ng/ml p24. For this purpose the
virus was pre-incubated either with medium or with different
concentrations of Idea-Ps for 1 h at room temperature. The
mixture was given to the cells for 24 h, followed by removal of the
cell culture supernatant, intensive washing and addition of fresh
medium either with or without Idea-Ps. To quantify viral infection
and propagation three different tests were applied after 4 days.
First, the number of formed syncytia per well was quantified
microscopically. Second, secretion of progenitor virus in the
culture supernatant was examined using the p24 assay described
above. Third, the number of infected cells can be investigated by
addition of the chromogenic substrate X-Gal, since viral infection
transactivates the LTR promoter inducing b-galactosidase pro-
duction. For this purpose the cells were washed with PBS followed
by fixing with 0.5% glutaraldehyde for 15 min at room
temperature. Afterwards this solution was replaced by PBS
containing 200 mg/ml X-Gal, 3 mM potassium ferricyanide,
3 mM potassium ferrocyanide, 1.3 mM MgCl2 (pH 7.4). After
incubation for 2–6 h at 37uC blue foci were counted microscop-
ically.
M8166 cells were incubated with 0.25 to 3 ng/ml virus pre-
incubated with medium with or without Idea-Ps as described
above. Viral infection and propagation was quantified by counting
the syncytia in the microscope.
Binding of Idea-P to GP120, CD4 as well as to PDI
quantified by ELISA
Full length and glycosylated recombinant gp120 LAV (IIIb),
gp120 LAV and recombinant CD4 were purchased from Protein
Sciences Corporation (Meriden, CT, USA). Protein Disulfide
Isomerase (PDI) was from Takara (Otsu, Japan). Binding of the
different Idea-Ps to gp120 IIIB, CD4 as well as to the PDI were
demonstrated in a standard ELISA. In brief, the bottom of the
wells of NUNC MaxiSorpTM polystyrene 96 well ELISA plates
were coated with gp120, CD4 or PDI, respectively (100 ng/well in
100 ml coating buffer) over night at 4uC. The selected coating and
blocking buffers were 15 mM disodium carbonate and 25 mM
sodium hydrogen carbonate buffer, pH 9.6, and 0.25% gelatine
solution with phosphate-buffered saline solution +0.05% Tween20
(PBS-T), respectively. The wells were blocked for 1 h at RT. Plates
were washed 4 times with 300 ml washing buffer (PBS-T) per well
and all residual washing buffer was removed. 100 ml Idea-P
samples or unaltered mother proteins were added to appropriate
wells and incubated at 37uC for 1 hour. The plates were washed
thoroughly and an antibody against HSA, Fibrinogen or
Antithrombin III (DAKO, Hamburg, Germany) was added.
Plates were washed again and a secondary peroxidase labeled
antibody was added to detect the primary antibody in concentra-
tions recommended by the manufacturer. 100 ml ATBS substrate
was given to each well, the plates were wrapped to shield from
light, incubated at room temperature and the absorbance was read
at OD492. Experiments run at least in triplicate.
Binding of Idea-P to gp120, to CD4 as well as to PDI using
Plasmone Resonance
Surface plasmon resonance (SPR) biosensors enable rapid and
label free sensing of biomolecular interactions. The SPR
phenomenon occurs when polarized light, under conditions of
total internal reflection, strikes an electrically conducting gold
layer. A Biacore 2000 and a Biacore 3000 system (BIACORE AB,
Sweden) were used. HIV-1-gp120, CD4 or PDI, respectively were
immobilized on a C5 sensor chip using amine coupling kit
(BIACORE AB). Conditions were as follows: running buffer
25 mM Tris, 10 mM NaCl, pH 7.4, 1 mM CaCl2, 1 mM MgCl2,
0.005% surfactant P-20; coupling buffer 10 mM NaAc pH 7.0;
HIV-1-gp120 20 ml (10 mg/ml), immobilized amount: 1158RU;
CD4 30 ml (6.3 mg/ml), immobilized amount 568RU; PDI 20 ml
(10 mg/ml), immobilized amount 1396 RU.
After the immobilisation free amino groups on the chip surface
were quenched with ethanolamine and the binding of Idea-Ps was
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investigated. As an example for other Idea-Ps the experimental
procedure for Idea-ATIII is given in detail. 50 ml Idea-ATIII was
injected in three different concentrations at a flow rate of 20 ml/
min. The protein solutions were diluted with sample buffer. With
increasing Idea-ATIII amounts the resulting signals increased.
Overlap sensorgrams, which show binding of Idea-ATIII to
immobilized HIV-1-gp120, CD4 and PDI and subsequent
dissociation were created. All the sensorgrams were corrected by
subtracting the signal from reference flow cell. The non-altered
original proteins and protein mixtures were used as controls.
Inhibition of Idea-P binding to gp120, CD4 or PDI,
respectively by SH-reactive substances
Dithiobis-nitrobenzoic acid (DTNB, Sigma, Taufkirchen, Ger-
many) (100 ml per well, 0.1 to 2.5 mM in PBS, pH 7.2) or para-
chloromercuriphenyl sulfonate (pCMPS, Sigma, Taufkirchen,
Germany) (100 ml, 10 to 300 mM in PBS, pH 7.2) were added to
immobilized gp120, immobilized CD4 or immobilized PDI in
wells of an ELISA-plate for 15 minutes, and unbound thiol-
reagent was washed away thoroughly. Afterwards the plates were
processed as described above to measure binding of Idea-P to
gp120, CD4 or PDI, respectively.
Amyloid-like structure of Idea-PP, Idea-HSA, Idea ATIII
As Maas et al have disclosed, that tPA, FXII as well as the
chaperone BiP are capable of binding proteins with amyloid
modules [66], binding of Idea-PP, Idea-HSA, Idea-ATII to all
three general amyloid recognizing tools was studied by an ELISA.
Recombinant tPA (ActilyseH) and coagulation factor FXII were
purchased from Boehringer Ingelheim (Ingelheim, Germany) or
Haemochrom. Diagnostica. (Essen, Germany), respectively. Re-
combinant human BiP was from StressmarqTM Biosciences Inc.
(Victoria, Canada).
Binding of the different Idea-Ps to tPA, FXII as well as to BiP
were demonstrated in a standard ELISA. In brief, the bottom of
the wells of NUNCMaxiSorpTM polystyrene 96 well ELISA plates
were coated with tPa, FXII or BiP, respectively (100 ng/well in
100 ml coating buffer) over night at 4uC. The selected coating and
blocking buffers were 15 mM disodium carbonate and 25 mM
sodium hydrogen carbonate buffer, pH 9.6, and 0.25% gelatine
solution with phosphate-buffered saline solution +0.05% Tween20
(PBS-T), respectively. The wells were blocked for 1 h at RT. The
plates were washed 4 times with 300 ml washing buffer (PBS-T) per
well and all residual washing buffer was removed. 100 ml Idea-PP,
Idea-HSA, Idea-ATIII samples or unaltered mother proteins were
added to appropriate wells and incubated at 37uC for 1 hour. The
plates were washed thoroughly and a specific antibody was added.
Plates were washed again and a secondary peroxidase labeled
antibody was added to detect the primary antibody in concentra-
tions recommended by the manufacturer. 100 ml ATBS substrate
was given to each well, the plates were wrapped to shield from
light, incubated at room temperature and the absorbance was read
at OD492. Experiments run at least in triplicate.
Supporting Information
Figure S1 Binding of Idea-PP, Idea-HSA or Idea-ATIII to
immobilised coagulation factor XII, tissue plasminogen
activator or the chaperone BiP. The binding to coagulation
factor FXII (A, B, C), to tPA (D, E, F) or to BiP (G, H, I) of altered
plasma proteins (Idea-PP, A, D, G), altered human serum albumin
(Idea-has, B, E, H) or altered antithrombin III (Idea-ATIII, C,F,I)
was determined by specific ELISA. The mean extinction 6 SD
from three parallel samples is presented.
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